SNGX · Soligenix, Inc.
Market Cap
$8.20M
Shares
21.77M
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2021-01-26 | U.S. Commercialization of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma | Webcast |
| 2020-12-22 | Phase 3 OM Results | Event |
| 2020-09-10 | CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine | Webcast |
| 2020-03-19 | Positive Phase 3 CTCL Results | Event |
Source: https://ir.soligenix.com/
Key facts
CIK
812796
CUSIP
834223604
13F (30d)
15 filings
15 filers
Visit website
Investor relations